Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Fig. 3

Scores of Psoriatic Arthritis Disease Activity Score (PASDAS) components at weeks 16, 52 and 104. The median value is denoted by symbol in the figure, and the upper and lower error bars represent third (Q3) and first (Q1) quartiles, respectively. n = number of patients in respective disease states at assessment. HDA High disease activity, LDA Low disease activity, MoDA Moderate disease activity, SF-36 MCS Short Form Health Survey Mental Component Summary, SJC Swollen joint count, TJC Tender joint count, VAS Visual analogue scale

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us